Investigational drug · Phase 2
ZED1227
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Celiac Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ZED1227"
First trial start
2024
Jun 10, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ZED1227", any sponsor or status.
Conditions studied
As listed on its trial records.
- Celiac Disease
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ZED1227" as an intervention, largest first.
- Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac DiseasePivotal-lookingRecruiting
Dr. Falk Pharma GmbHIndustry
NCT07298343 · 356 participants (planned) · Start Jun 10, 2024 · Primary completion Aug 2027
Drug: ZED1227 + SIGE · For: Celiac Disease
Sites: Mainz, Germany
- Different Doses of ZED1227 vs. Placebo in NAFLDPivotal-lookingCompleted
Dr. Falk Pharma GmbHIndustry
NCT05305599 · 186 participants · Start Apr 19, 2022 · Primary completion Jun 7, 2023
Drug: ZED1227; Placebo · For: NAFLD; Liver Fibrosis
Sites: Mainz, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Therapeutic TG2 inhibition reverses systemic multiomic dysregulation in celiac disease.
Dotsenko V, Le HH, Rajik S, et al. · BMC Med 2026
- Is There a Future Without Gluten Restrictions for Celiac Patients? Update on Current Treatments.
Girbal-González M, Pérez-Cano FJ · Nutrients 2025
- New Therapeutic Challenges in Pediatric Gastroenterology: A Narrative Review.
Dipasquale V, Romano C · Healthcare (Basel) 2025
- Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease.
Dotsenko V, Tewes B, Hils M, et al. · Nat Immunol 2024
- Celiac disease: Hope for new treatments beyond a gluten-free diet.
D'heedene M, Vanuytsel T, Wauters L · Clin Nutr 2024
- The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment.
Isola J, Mäki M, Hils M, et al. · Int J Mol Sci 2023
Also in development for Celiac Disease
- AmlitelimabSAR445229Phase 39 trials
Sanofi · Dermatitis Atopic, Coeliac Disease, Celiac Disease
- TEV-53408Phase 32 trials
Teva · Vitiligo, Celiac Disease
- Larazotide AcetatePhase 31 trial
Interlude Biopharma Co. · Celiac Disease, Celiac Disease in Adolescents
- DONQ52Phase 21 trial
Chugai Pharmaceutical · Celiac Disease
- FB102Phase 21 trial
Forte Biosciences, Inc. · Celiac Disease
- KAN-101Phase 21 trial
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA · Celiac Disease, Coeliac Disease
- TAK-101Phase 21 trial
Takeda · Celiac Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.